OPK - オプコ・ヘルス （Opko Health Inc.）

OPKO Health Inc. (NASDAQ:OPK) traded at $1.12 at close of the session on Monday, 03/06/23, made a downward move of -3.45% on its previous day’s price. Looking at the stock we see that its previous close was $1.16 and the beta (5Y monthly) reads 1.68 with the day’s price range being $1.11 – $1.17. In … OPKO Health Inc. (NASDAQ: OPK) Is Down -10.40% Year-To-Date, But There Is Speculation That It Will Rally Read More »

OPKO Health''s losses continue to mount, and revenue falls from diagnostics paint an unhealthy investment picture for retail value investors. Read why OPK stock is a Hold.

Currently, OPKO Health Inc.’s (OPK) stock is trading at $1.12, marking a gain of 6.13% from last night’s close. At this price, the stock is -70.24% below its 52-week high of $3.78 and 12.50% above its 52-week low of $1.00. Based on the past 30-day period, the stock price is -23.84% below the high and […]

OPK has seen its SMA50 which is now -20.03%. In looking the SMA 200 we see that the stock has seen a -49.02%. CYBN has seen its SMA50 which is … The post Current Stocks in the Spotlight: OPKO Health, Inc. (NASDAQ:OPK), Cybin Inc. (AMEX:CYBN) appeared first on Stocks Equity .

OPK earnings call for the period ending December 31, 2022.

Opko Health with ticker code (OPK) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 8.5 and 5.5 calculating the average target price we see 6.88. Now with the previous closing price of 3.54 this would indicate that there is a potential upside of 94.4%. There is a 50 day moving average of 3.28 and the 200 day moving average is 3.77. The market capitalisation for the company is $2,344m. Company Website: https://www.opko.com [stock_market_widget type="chart" template="basic" color="green" assets="OPK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $4,556m based on the market concensus. OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

COVID-19 test maker, OPKO Health <> is trading higher on Tuesday after Chief Executive and Chairman, Dr

Saol Therapeutics is collaborating with OPKO Health''s (OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase…

Opko Health with ticker code (OPK) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 8.5 and 5.5 calculating the average target price we see 6.88. Now with the previous closing price of 3.54 this would indicate that there is a potential upside of 94.4%. There is a 50 day moving average of 3.28 and the 200 day moving average is 3.77. The market capitalisation for the company is $2,344m. Company Website: https://www.opko.com [stock_market_widget type="chart" template="basic" color="green" assets="OPK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $4,556m based on the market concensus. OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

COVID-19 test maker, OPKO Health <> is trading higher on Tuesday after Chief Executive and Chairman, Dr

Saol Therapeutics is collaborating with OPKO Health''s (OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase…